New Pfizer reduces oncology focus
This article was originally published in Scrip
As Pfizer's new R&D strategy emerges in the wake of its acquisition of Wyeth, it appears that the company is moving away from a push in recent years to become a bigger player in the oncology market.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.